Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The increased risk of mortality in patients with gout is increasingly recognized, and multiple guidelines call for better management of this disease and its comorbidities. A new study, however, has found that excess mortality in patients with gout has remained unchanged since 1999.
Janus kinase (JAK) inhibitors are emerging therapeutic agents for the treatment of rheumatic inflammatory diseases. In this Review, the author outlines the safety profile of JAK inhibitors, discussing the potential adverse effects associated with these drugs, such as malignancy, infections and reactivation of herpes zoster.
Updated recommendations for the management of axial spondyloarthritis provide a useful framework for physicians treating this disease. However, the guidance on use of biologic therapies and treat-to-target strategies seems to raise more questions than it answers.
In this Review, the authors discuss the therapeutic application of haematopoietic stem cell transplantation in different autoimmune diseases, describing the immunological mechanisms and the risks and benefits of this procedure.
New guidelines from EULAR and the Paediatric Rheumatology European Society recommend a set of quality standards for the care of young adults with childhood-onset rheumatic diseases during their transfer from paediatric to adult rheumatology care providers. Can the application of these guidelines prevent patients from getting lost in the system?
Ectopic lymphoid structures have been identified in the target organs of a subset of patients with rheumatic autoimmune diseases. This Review describes these structures and summarizes our current understanding of how they form, function and contribute to autoimmunity.
This Review outlines what a rheumatologist needs to know about the development and advances in CRISPR/Cas9 genome editing technologies. The authors discuss the direct applications to rheumatic diseases, which are currently limited but are certain to increase rapidly in the near future.